Israël - Hebreeuws - Ministry of Health

taro pharmaceutical industries ltd - warfarin sodium - טבליה - warfarin sodium 2.5 mg - warfarin - warfarin - coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonary embolism. coumadin is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. coumadin is indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction.

Israël - Hebreeuws - Ministry of Health

taro pharmaceutical industries ltd - warfarin sodium - טבליה - warfarin sodium 3 mg - warfarin - warfarin - coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonary embolism. coumadin is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. coumadin is indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction.

Israël - Hebreeuws - Ministry of Health

taro pharmaceutical industries ltd - warfarin sodium - טבליה - warfarin sodium 4 mg - warfarin - warfarin - coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonary embolism. coumadin is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. coumadin is indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction.

Israël - Hebreeuws - Ministry of Health

taro pharmaceutical industries ltd - warfarin sodium - טבליה - warfarin sodium 5 mg - warfarin - warfarin - coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonar embolis. coumadin is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. coumadin is indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction.

Israël - Hebreeuws - Ministry of Health

taro pharmaceutical industries ltd - warfarin sodium - טבליה - warfarin sodium 6 mg - warfarin - warfarin - coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonar embolis. coumadin is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. coumadin is indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction.

Israël - Hebreeuws - Ministry of Health

taro pharmaceutical industries ltd - warfarin sodium - טבליה - warfarin sodium 7.5 mg - warfarin - warfarin - coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonary embolism. coumadin is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. coumadin is indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction.

Israël - Hebreeuws - Ministry of Health

taro pharmaceutical industries ltd - warfarin sodium - טבליה - warfarin sodium 10 mg - warfarin - warfarin - coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonary embolism. coumadin is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. coumadin is indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction.

Israël - Hebreeuws - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - dalteparin sodium - תמיסה להזרקה - dalteparin sodium 5000 iu / 0.2 ml - dalteparin - dalteparin - prevention of clotting during haemodialysis and haemofiltration in connection with acute renal failure or chronic renal insufficiency. treatment of acute deep venous thrombosis and/or pulmonary embolism.unstable coronary artery disease. thromboprophylaxis in conjunction with surgery. prophylaxis in patients with substantially increased risk for venous thromboembolism and that are temporarily immobilized due to acute illness such as cardiac insufficiency respiratory insufficiency and severe infections.cancer patients : treatment and secondary prevention of deep-vein thrombosis and/or pulmonary embolism.

Israël - Hebreeuws - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - dalteparin sodium - תמיסה להזרקה - dalteparin sodium 2500 iu / 0.2 ml - dalteparin - dalteparin - prevention of clotting during haemodialysis and haemofiltration in connection with acute renal failure or chronic renal insufficiency. treatment of acute deep venous thrombosis and/or pulmonary embolism. unstable coronary artery disease. thromboprophylaxis in conjunction with surgery. prophylaxis in patients with substantially increased risk for venous thromboembolism and that are temporarily immobilized due to acute illness such as cardiac insufficiency respiratory insufficiency and severe infections.cancer patients : treatment and secondary prevention of deep-vein thrombosis and/or pulmonary embolism.

Israël - Hebreeuws - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - dalteparin sodium - תמיסה להזרקה - dalteparin sodium 2500 iu/ml - dalteparin - dalteparin - prevention of clotting during haemodialysis and haemofiltration in connection with acute renal failure or chronic renal insufficiency. treatment of acute deep venous thrombosis and/or pulmonary embolism. unstable coronary artery disease. thromboprophylaxis in conjunction with surgery. prophylaxis in patients with substantially increased risk for venous thromboembolism and that are temporarily immobilized due to acute illness such as cardiac insufficiency respiratory insufficiency and severe infections. cancer patients : treatment and secondary prevention of deep-vein thrombosis and/or pulmonary embolism.